XtalPi, a Shenzhen-based drug discovery and robotics company, reported a 615% rise in first-half revenue from its drug discovery business, reaching 435 million yuan (US$61 million), after receiving US$51 million from a licensing deal with US-based DoveTree.

The agreement gives DoveTree exclusive global rights to develop and commercialize drug candidates discovered by XtalPi using its AI-powered platform, and includes an additional US$49 million payment in the next six months, the company said.

XtalPi’s overall revenue for the first half rose 404% to 517.1 million yuan (US$72.5 million), while net profit reached 141.6 million yuan (US$19.9 million), reversing a loss from the previous year.

Revenue from its intelligent robotics segment increased 96% to 81.9 million yuan (US$11.5 million).

🔗 Source: South China Morning Post

🧠 Food for thought

1️⃣ Biotech licensing shifts toward milestone-heavy deals as risk dynamics change

XtalPi’s $6 billion DoveTree agreement exemplifies how biotech partnerships now emphasize future performance over upfront commitments1.

The deal structure, with $51 million collected upfront and $49 million due in six months, reflects broader industry trends where upfront payments dropped to just 5% of total deal values in 2024, down from 13% in 20192.

This shift makes sense given the patent cliff facing major pharmaceutical companies, with an estimated $240 billion in sales at risk by 2030 for the top 25 biopharma firms2.

Companies like DoveTree are essentially betting on XtalPi’s claimed ability to compress drug discovery timelines from four years to one or two years using AI and robotics—a promise that commands premium valuations but requires proof through actual drug candidates1.

The milestone structure allows Western companies to access Chinese innovation while managing execution risk, particularly important given XtalPi’s current cash burn of CN¥684 million despite strong revenue growth3.

2️⃣ China emerges as innovation source rather than just manufacturing partner

The surge in US-China biotech licensing—from just two deals a year earlier to 14 deals worth $18.3 billion in the first half of 2025—signals China’s transformation from manufacturing hub to innovation center1.

Chinese biotech firms now contribute 23% of the global innovative drug pipeline and have added over 4,100 innovative drugs to their pipelines since 2022, representing 31% of the global total45.

This shift is particularly evident in advanced therapeutic areas where Chinese companies lead development, including antibody-drug conjugates and CAR-T therapies4.